

CRITICAL AND URGENT CARE I PANEL

EDITORIAL BOARD LIAISON

Clarence Chant, Pharm.D., FCCP, FCSHP, BCPS
Clinical Pharmacy Specialist
Critical Care/Research, Pharmacy Department
St. Michael's Hospital
Assistant Professor
Leslie Dan Faculty of Pharmacy
University of Toronto
Toronto, Ontario, Canada

Detroit, Michigan
Adjunct Assistant Professor
Eugene Applebaum College of Pharmacy
and Health Science
Wayne State University

Marwan M. Kazimi, M.D.
Senior Staff Surgeon
Department of Surgery and Transplant Institute
Henry Ford Health Systems
Detroit, Michigan

OBSTETRIC EMERGENCIES IN THE ICU

Author

Julie J. Kelsey, Pharm.D.
Pharmacy Clinical Specialist, Obstetrics and Gynecology
Department of Pharmacy Services
University of Virginia Health System
Charlottesville, Virginia

Reviewers

Clarence Chant, Pharm.D., FCCP, BCPS, FCSHP
Clinical Pharmacy Specialist
Critical Care/Research, Pharmacy Department
St. Michael's Hospital
Assistant Professor
Leslie Dan Faculty of Pharmacy
University of Toronto
Toronto, Ontario, Canada

Ronald A. Floyd, Pharm.D., M.S., FCCP, BCPS
Pharmacy Specialist
Department of Pharmacy
Sharp Mary Birch Hospital for Women and Newborns
San Diego, California

ICU CONSIDERATIONS AFTER LIVER TRANSPLANT

Authors

Iman Bajjoka, Pharm.D., FCCP, BCPS
Director, Transplant Clinical Research
Henry Ford Transplant Institute
Henry Ford Health System

Reviewers

Anne L. Hume, Pharm.D., FCCP, BCPS
Professor of Pharmacy
Department of Pharmacy Practice
University of Rhode Island
Kingston, Rhode Island
Adjunct Professor of Family Medicine
Alpert School of Medicine at Brown University
Providence, Rhode Island

Kerri Kraft, Pharm.D., BCPS
Clinical Pharmacy Specialist, Solid Organ Transplant
Department of Pharmacy
Kaiser Permanente Colorado
Aurora, Colorado

MANAGING CARDIOVASCULAR SURGERY INTENSIVE CARE UNIT PATIENTS

Author

Danielle M. Blais, Pharm.D., BCPS
Clinical Assistant Professor
Cardiothoracic Surgery Specialty Pharmacist
Department of Pharmacy
The Ohio State University Medical Center
Columbus, Ohio

Reviewers

Robert J. DiDomenico, Pharm.D.
Clinical Associate Professor
Cardiovascular Clinical Pharmacist
University of Illinois at Chicago
University of Illinois Medical Center at Chicago
Chicago, Illinois

Marianne McCollum, Ph.D., BSPHarm, BCPS
Assistant Dean for Assessment
School of Pharmacy
Rueckert-Hartman College for Health Professions
Regis University
Denver, Colorado

Karen M. Whalen, BSPHarm, BCPS
Drug Information Pharmacist
Department of Pharmacy
St. Joseph's Hospital
Syracuse, New York

***The American College of Clinical Pharmacy and the
authors thank the following individuals for their careful
review of the Book 2, Critical and Urgent Care I chapters:***

Mary C. Gurnee, Pharm.D.
Pharmacist Consultant
Overland Park, Kansas

Dianne M. Brundage, Pharm.D., FCCP, BCPS, BCOP
Oncology Clinical Pharmacy Specialist
Park Nicollet Health Services Methodist Hospital
Minneapolis, Minnesota

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Elizabeth Dodds Ashley (Shering-Plough, Merck, Pfizer); Danielle Blais (Facts-Care, The Medicines Company); Robert J. DiDomenico (Scios, The Medicines Company, Sanofi-Aventis, Merck, ARCA Biopharma); Ronald A. Floyd (California Society of Health-System Pharmacists); Anne Julie Frenette (Baxter, Merck Frosst, Eli Lilly); Krystal K. Haase (*Pharmacology Weekly*); Brian A. Hemstreet (Conexus Health); Lisa C. Hutchison (Arkansas Medicaid); Judith Jacobi (Society of Critical Care Medicine, American Board of Applied Toxicology, American Association of Poison Control Centers [spouse or significant other]); Sandra L. Kane-Gill (Baxter, Hospira, Cannon Pharmaceuticals); Steven J. Martin (The Medicines Company, Astellas); Steven Pass (The Medicines Company); John Papadopoulos (Wyeth); Michelle Richardson (Amgen, QualityMetric); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, *Annals of Pharmacotherapy*); Jeffrey T. Sherer (Sturge-Weber Foundation); Daniel J.G. Thirion (Wyeth, Schering-Plough, Boehringer-Ingelheim [spouse or significant other]); David Williamson (Boehringer-Ingelheim)

Stock Ownership: Katherine H. Chessman (Procter & Gamble [stock owned by spouse or significant other]); Ronald A. Floyd (Eli Lilly, Johnson & Johnson, Pfizer); Lisa C. Hutchison (Cardinal Health); Julie J. Kelsey (Pfizer)

Royalties: Lisa C. Hutchison (ASHP); Judith Jacobi (Fougera [spouse or significant other]);

Grants: Elizabeth Dodds Ashley (Astellas, Schering-Plough [two grants]); Michael L. Bentley (Carilion Clinic, Hospira); Danielle Blais (ASHP); Judy W.M. Cheng (St. Jude's Medical

Research Center); Robert J. DiDomenico (Johnson & Johnson, AHRQ, ACCP Research Institute); Linda Dresser (Palumed [two grants]); Anne Julie Frenette (Aventis Pharma); Brian A. Hemstreet (AstraZeneca); Anne L. Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer-Ingelheim, National Institutes of Health); Judith Jacobi (Luminous Medical, Amgen); Sandra L. Kane-Gill (Ortho McNeil); Scott T. Micek (Astellas Pharma, Ortho-McNeil-Janssen, Xcenda); Asad Patanwala (ASHP Foundation); Michelle Richardson (NIH NIDDK [two grants]); Christine M. Stork (Glaxo); Daniel J.G. Thirion (Wyeth Canada, Pfizer Canada)

Honoraria: Elizabeth Dodds Ashley (Merck, Schering-Plough); Danielle Blais (Bayer, Pfizer); Robert J. DiDomenico (Bristol-Myers Squibb, Sanif Pharmaceuticals, Sanofi-Aventis U.S., ACCP, APhA); Sandy J. Estrada (AdvanD, Biomeneux); Steven J. Martin (Ortho-McNeil – PriCara); Scott T. Micek (Merck, Pfizer); Steven Pass (Pfizer); John Papadopoulos (Wyeth, Boehringer-Ingelheim); Michelle Richardson (Amgen); Daniel J.G. Thirion (Wyeth, Merck Frosst); David Williamson (Boehringer-Ingelheim)

Other:

Nothing to Disclose: Iman E. Bajjoka, Jennifer M. Blanchard, Mitchell Buckley, Mary C. Byrne, Clarence Chant, David M. DiPersio, Wade Flowers, Marwan M. Kazimi, Tyree H. Kiser, Kerri Kraft, Jaclyn M. LeBlanc, Marianne McCollum, Marc M. Perreault, Garrett E. Schramm, Michael C. Thomas, Karen Whalen

ROLE OF ACCP: ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmaceutical Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

ROLE OF BPS: The Board of Pharmaceutical Specialties is an autonomous certification agency of the American Pharmacists Association. BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at www.bpsweb.org/recertification/general.cfm. Other questions regarding recertification should be directed to:

Board of Pharmaceutical Specialties
2215 Constitution Avenue N.W.
Washington, DC 20037
(202) 429-7591
www.bpsweb.org